Bausch + Lomb said its glaucoma eye drop missed the primary endpoint in a mid-stage trial, failing to replicate visual-function improvements seen in an earlier smaller study. The miss raises uncertainty on clinical effectiveness and potential development success, likely weighing on sentiment toward the program.
Bausch + Lomb said its glaucoma eye drop missed the primary endpoint in a mid-stage trial, failing to replicate visual-function improvements seen in an earlier smaller study. The miss raises uncertainty on clinical effectiveness and potential development success, likely weighing on sentiment toward the program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
